During the past decade, UCL Cancer Institute conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "UCL Cancer Institute" are "Breast Cancer" (3 trials), "Hereditary Breast/Ovarian Cancer (brca1, brca2)" (1 trials), "Infertility" (1 trials), "Menopausal Symptoms" (1 trials) and "brca1 Mutation Carrier" (1 trials). Many other conditions were trialed in "UCL Cancer Institute" in a lesser frequency.

Most popular intervention types in "UCL Cancer Institute" are "Drug" (3 trials), "Procedure" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "adjuvant therapy" (2 trials), "cyclophosphamide" (2 trials), "capecitabine" (1 trials), "carboplatin" (1 trials) and "docetaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "UCL Cancer Institute" are 2 trials for "Female" genders and 1 trials for "All" genders.

Currently, there are NaN active trials in "UCL Cancer Institute". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in UCL Cancer Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in UCL Cancer Institute, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".